Cargando…
The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients
OBJECTIVE: To explore the clinical features and prognoses of dermatomyositis (DM) associated with a double-positive anti-MDA5 and anti-aminoacyl-tRNA synthetase (anti-ARS) antibody presentation. METHODS: We retrospectively analyzed 1280 consecutive patients with idiopathic inflammatory myopathy (IIM...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468482/ https://www.ncbi.nlm.nih.gov/pubmed/36110863 http://dx.doi.org/10.3389/fimmu.2022.987841 |
_version_ | 1784788420856381440 |
---|---|
author | Chen, Xixia Zhang, Lu Jin, Qiwen Lu, Xin Lei, Jieping Peng, Qinglin Wang, Guochun Ge, Yongpeng |
author_facet | Chen, Xixia Zhang, Lu Jin, Qiwen Lu, Xin Lei, Jieping Peng, Qinglin Wang, Guochun Ge, Yongpeng |
author_sort | Chen, Xixia |
collection | PubMed |
description | OBJECTIVE: To explore the clinical features and prognoses of dermatomyositis (DM) associated with a double-positive anti-MDA5 and anti-aminoacyl-tRNA synthetase (anti-ARS) antibody presentation. METHODS: We retrospectively analyzed 1280 consecutive patients with idiopathic inflammatory myopathy (IIM). Individuals with anti-MDA5 and anti-ARS antibodies (anti-MDA5+/ARS+) were compared to anti-MDA5-/ARS+ and anti-MDA5+/ARS- control individuals based on clinical, pulmonary radiological characteristics, treatment, and follow-up information. RESULTS: Six individuals (0.47%) presented with anti-MDA5+/ARS+; of these, 2 (33.3%) were anti-PL-12+, 2 (33.3%) were anti-Jo-1+, 1 (16.7%) was anti-EJ+, and 1 (16.7%) was anti-PL-7+. Hallmark cutaneous manifestations, including Gottron’s sign (100%), heliotrope rash (50%), mechanic’s hand (66.7%), and skin ulcers (16.7%) were common. Anti-MDA5+/ARS+ patients tended to have higher ferritin levels (p = 0.038) than anti-MDA5-/ARS+ group, and higher CD4+ T-cell counts (p = 0.032) compared to the anti-MDA5+/ARS- group. Radiologically, NSIP with OP overlap was predominant (60%). Consolidation (60%), ground-glass attenuation (GGA) (80%), traction bronchiectasis (80%), and intralobular reticulation (100%) were common in anti-MDA5+/ARS+ individuals. All were diagnosed with ILD and 50% were categorized as RPILD. All patients received glucocorticoids combined with one or more immunosuppressants. Most (83.3%) had a good prognosis following treatment, but there was no difference in the survival rate between the three subgroups. CONCLUSION: Presentation with anti-MDA5+/ARS+ DM was rare. The clinical and radiological characteristics of anti-MDA5+/ARS+ DM combined the features of anti-MDA5+ and anti-ARS+ individuals. Individuals with anti-MDA5+/ARS+ antibodies may respond well to glucocorticoid therapy; glucocorticoids combined with one or more immunosuppressants may be considered a basic treatment approach. |
format | Online Article Text |
id | pubmed-9468482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94684822022-09-14 The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients Chen, Xixia Zhang, Lu Jin, Qiwen Lu, Xin Lei, Jieping Peng, Qinglin Wang, Guochun Ge, Yongpeng Front Immunol Immunology OBJECTIVE: To explore the clinical features and prognoses of dermatomyositis (DM) associated with a double-positive anti-MDA5 and anti-aminoacyl-tRNA synthetase (anti-ARS) antibody presentation. METHODS: We retrospectively analyzed 1280 consecutive patients with idiopathic inflammatory myopathy (IIM). Individuals with anti-MDA5 and anti-ARS antibodies (anti-MDA5+/ARS+) were compared to anti-MDA5-/ARS+ and anti-MDA5+/ARS- control individuals based on clinical, pulmonary radiological characteristics, treatment, and follow-up information. RESULTS: Six individuals (0.47%) presented with anti-MDA5+/ARS+; of these, 2 (33.3%) were anti-PL-12+, 2 (33.3%) were anti-Jo-1+, 1 (16.7%) was anti-EJ+, and 1 (16.7%) was anti-PL-7+. Hallmark cutaneous manifestations, including Gottron’s sign (100%), heliotrope rash (50%), mechanic’s hand (66.7%), and skin ulcers (16.7%) were common. Anti-MDA5+/ARS+ patients tended to have higher ferritin levels (p = 0.038) than anti-MDA5-/ARS+ group, and higher CD4+ T-cell counts (p = 0.032) compared to the anti-MDA5+/ARS- group. Radiologically, NSIP with OP overlap was predominant (60%). Consolidation (60%), ground-glass attenuation (GGA) (80%), traction bronchiectasis (80%), and intralobular reticulation (100%) were common in anti-MDA5+/ARS+ individuals. All were diagnosed with ILD and 50% were categorized as RPILD. All patients received glucocorticoids combined with one or more immunosuppressants. Most (83.3%) had a good prognosis following treatment, but there was no difference in the survival rate between the three subgroups. CONCLUSION: Presentation with anti-MDA5+/ARS+ DM was rare. The clinical and radiological characteristics of anti-MDA5+/ARS+ DM combined the features of anti-MDA5+ and anti-ARS+ individuals. Individuals with anti-MDA5+/ARS+ antibodies may respond well to glucocorticoid therapy; glucocorticoids combined with one or more immunosuppressants may be considered a basic treatment approach. Frontiers Media S.A. 2022-08-30 /pmc/articles/PMC9468482/ /pubmed/36110863 http://dx.doi.org/10.3389/fimmu.2022.987841 Text en Copyright © 2022 Chen, Zhang, Jin, Lu, Lei, Peng, Wang and Ge https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Chen, Xixia Zhang, Lu Jin, Qiwen Lu, Xin Lei, Jieping Peng, Qinglin Wang, Guochun Ge, Yongpeng The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients |
title | The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients |
title_full | The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients |
title_fullStr | The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients |
title_full_unstemmed | The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients |
title_short | The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients |
title_sort | clinical features and prognoses of anti-mda5 and anti-aminoacyl-trna synthetase antibody double-positive dermatomyositis patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468482/ https://www.ncbi.nlm.nih.gov/pubmed/36110863 http://dx.doi.org/10.3389/fimmu.2022.987841 |
work_keys_str_mv | AT chenxixia theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT zhanglu theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT jinqiwen theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT luxin theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT leijieping theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT pengqinglin theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT wangguochun theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT geyongpeng theclinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT chenxixia clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT zhanglu clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT jinqiwen clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT luxin clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT leijieping clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT pengqinglin clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT wangguochun clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients AT geyongpeng clinicalfeaturesandprognosesofantimda5andantiaminoacyltrnasynthetaseantibodydoublepositivedermatomyositispatients |